Evidence map›Paper›PMID 40161303›Full record

ArticleEuropean heart journal open2025

Remnant cholesterol concentrations best explain the cardiovascular benefit of APOC3 genetic inhibition: a drug target Mendelian randomization study.

Eloi Gagnon, Dipender Gill, Stephen Burgess, Benoit J Arsenault

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eloi GagnonCentre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Y-3106, 2725 chemin Ste-Foy, Québec, QC, Canada G1V 4G5.ORCID https://orcid.org/0000-0002-7483-1371
Dipender GillDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, 90 Wood Ln, London W12 0BZ, UK.
Stephen BurgessMRC Biostatistics Unit, University of Cambridge, East Forvie Building, Forvie, Robinson Way, Cambridge CB2 0SR, UK.ORCID https://orcid.org/0000-0001-5365-8760
Benoit J ArsenaultCentre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Y-3106, 2725 chemin Ste-Foy, Québec, QC, Canada G1V 4G5.ORCID https://orcid.org/0000-0003-2240-8456

Funding

Wellcome Trust 225790
6 · The paper itself

Abstract

Aims: Apolipoprotein C-III (APOC3) inhibitors are approved for hypertriglyceridaemia. Genetic evidence suggests that APOC3 inhibition may also prevent coronary artery disease (CAD), but mechanisms remain unclear. Methods and results: To clarify how APOC3 inhibition could prevent CAD, we performed two-step cis-Mendelian randomization using genetic variants in the Conclusion: Remnant cholesterol best explains the mechanism through which APOC3 inhibition could prevent CAD. APOC3 inhibition may influence fasting remnant cholesterol to a greater extent than non-fasting remnant cholesterol. People with high levels of remnant cholesterol could benefit from APOC3 inhibition.

Indexed as

Apolipoprotein C3Coronary artery diseaseDrug target MRMendelian randomization

Identifiers

PMID40161303
PMCPMC11951255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.